CRISPR Therapeutics shareholders approve 1.7M share increase to stock plan, capital band, board reduction

The Company’s amended and restated Articles of Association become effective upon registration in the Commercial Register in the canton of Zug, Switzerland on or about June 9, 2023, subject to the approval by the Swiss Federal Commercial Authority.

Proposal 5 –Election or Re-election of the Members of the Compensation Committee Ali Behbahani, M.D., H. Edward Fleming, Jr., M.D., Simeon J. George, M.D., and John T. Greene, were each duly elected and re-elected, as applicable, as members of the Company’s Compensation Committee of the Board of Directors. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Ali Behbahani, M.D. 22,931,018 18,555,470 77,441 16,807,924 H Edward Fleming Jr., M.D. 39,628,150 1,854,312 81,467 16,807,924 Simeon J. George, M.D. 39,578,104 1,906,247 79,578 16,807,924 John T. Greene 38,619,814 2,829,336 114,779 16,807,924

Proposal 3 – Discharge of the Members of the Board of Directors and Executive Committee The discharge of the members of the Company’s Board of Directors and the Executive Committee from personal liability for their activities during the year ended December 31, 2022 was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 41,154,717 325,296 83,916 16,807,924

Proposal 4 – Re-election of the Members and Chair of the Board of Directors Rodger Novak, M.D., Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elected as members of the Company’s Board of Directors and Rodger Novak, M.D. was duly re-elected as the chairman of the Board of Directors. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Rodger Novak, M.D. 41,225,578 270,501 67,850 16,807,924 Samarth Kulkarni, Ph.D. 40,484,397 1,013,593 65,939 16,807,924 Ali Behbahani, M.D. 23,098,811 18,392,522 72,596 16,807,924 Maria Fardis, Ph.D. 41,210,171 285,063 68,695 16,807,924 H Edward Fleming Jr., M.D. 40,927,328 564,987 71,614 16,807,924 Simeon J. George, M.D. 40,902,631 589,614 71,684 16,807,924 John T. Greene 40,337,357 1,152,556 74,016 16,807,924 Katherine A. High, M.D. 41,120,246 374,090 69,593 16

The endorsement of the 2022 Compensation Report was approved on a non-binding basis. The results of the non-binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 26,387,171 15,034,482 142,276 16,807,924

The total variable compensation for members of the Executive Committee for the current year ending December 31, 2023 was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 31,310,823 10,126,213 126,893 16,807,924

Proposal 2 – Approval of the Appropriation of Financial Results The proposal to carry forward the net income resulting from the appropriation of financial results was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 57,987,144 188,211 196,498 0

The total non-performance related compensation for members of the Executive Committee from July 1, 2023 to June 30, 2024 was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 31,071,592 10,363,680 128,657 16,807,924

The total non-performance-related compensation for members of the Board of Directors from the Annual Meeting to the 2024 annual general meeting of shareholders was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 41,036,078 389,401 138,450 16,807,924

The grant of equity for members of the Board of Directors from the Annual Meeting to the 2024 annual general meeting of shareholders was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 28,523,942 12,922,502 117,485 16,807,924

Proposal 1 – Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2022 The Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2022 were approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 58,042,258 156,560 173,035 0

The grant of equity for members of the Executive Committee from the Annual Meeting to the 2024 annual general meeting of shareholders was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 27,342,115 14,113,037 108,777 16,807,924